News

• NICE recommends Jyseleca® ▼(filgotinib) on NHS in landmark decision for rheumatoid arthritis
  01/21/2021 / 08:08 - GlobeNewswire
•  
• Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer
  01/20/2021 / 08:00 - GlobeNewswire
•  
• Gilead holds 25.54% of Galapagos shares
  01/11/2021 / 22:01 - GlobeNewswire
•  
• OXURION to Participate in Upcoming Investor Meetings
  01/07/2021 / 08:00 - GlobeNewswire
•  
• Galapagos to present at 39th Annual J.P. Morgan Healthcare Conference
  01/06/2021 / 15:30 - GlobeNewswire
•  
• Selvita completes acquisition of Fidelta from Galapagos
  01/04/2021 / 22:01 - GlobeNewswire
•  
• Galapagos’ CEO makes donation of €10 million in the form of personal shares to African Parks
  12/23/2020 / 18:00 - GlobeNewswire
•  
• Gilead  and  Galapagos  announce  New  Commercialization  and  Development  Agreement  for  Jyseleca®  (filgotinib)  
  12/15/2020 / 22:15 - GlobeNewswire
•  
• SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
  12/13/2020 / 00:50 - GlobeNewswire
•  
• Galapagos increases share capital through subscription right exercises
  12/04/2020 / 22:01 - GlobeNewswire
•  
• Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
  12/01/2020 / 22:01 - GlobeNewswire
•  
• Galapagos reports positive topline results with GLPG1205 in IPF patients in PINTA Proof-of-Concept trial 
  11/30/2020 / 22:01 - GlobeNewswire
•  
• Selvita to acquire Fidelta from Galapagos
  11/23/2020 / 22:15 - GlobeNewswire
•  
• First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial
  11/09/2020 / 22:01 - GlobeNewswire
•  
• OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices
  11/09/2020 / 07:30 - GlobeNewswire